ArticleJournal of molecular neuroscience : MN2026
Integrated Expression and Bioinformatic Analysis of AKT-Associated lncRNAs Suggests UCA1 as a Candidate Biomarker for Bipolar Disorder.
Article in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bipolar disorder (BD) is a severe psychiatric disorder characterized by recurrent disturbances in mood and behavior. Given the reported involvement of the AKT signaling pathway in BD, we investigated the expression of three AKT-associated long non-coding RNAs (LINC-ROR, MALAT1, and UCA1) in peripheral blood samples from patients with BD and healthy controls. Furthermore, we performed exploratory bioinformatic analyses to identify potential lncRNA-miRNA and lncRNA-RNA-binding protein interaction networks. In the present study, we evaluated the expression profiles of three AKT signaling pathway-associated lncRNAs, namely LINC-ROR, MALAT1, and UCA1, in peripheral blood samples from patients with BD. We compared these findings with those from healthy control subjects. Additionally, an in silico analysis was performed to investigate potential microRNA (miRNA) binding sites within these lncRNAs and to assess their interactions with RNA-binding proteins (RBPs), thereby providing further insight into their potential regulatory roles in BD pathogenesis. MALAT1 and UCA1 expression levels were significantly higher in patients with BD than in healthy controls. Although LINC-ROR expression showed a trend toward downregulation, the difference did not remain statistically significant after Bonferroni correction for multiple comparisons. Among the investigated lncRNAs, UCA1 exhibited the strongest discriminatory performance in differentiating individuals with BD from control subjects, achieving an area under the receiver operating characteristic curve (AUC) of 0.75 (P < 0.0001, 95% CI: 65%-84%). Previous evidence demonstrating the involvement of the AKT signaling pathway in the pathogenesis of BD further supports the hypothesis that dysregulation of pathway-associated lncRNAs contributes to the disorder. These findings support the involvement of AKT-associated lncRNAs in BD pathophysiology and suggest that UCA1 may represent a candidate biomarker requiring further validation in larger independent cohorts.
Indexed as
Identifiers
42474872What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.